Product Description
A tamoxifen metabolite with both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afimoxifene)
Mechanisms of Action: ER Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ascend
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Ductal Breast Carcinoma|Intraductal Noninfiltrating Carcinoma|Ductal Carcinoma|Breast Cancer|Mastodynia|Soft Tissue Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NU 18B05 | P2 |
Recruiting |
Ductal Carcinoma|Intraductal Noninfiltrating Carcinoma|Ductal Breast Carcinoma|Breast Cancer |
2024-01-31 |
|
| NCI-2017-00244 | P2 |
Completed |
Breast Cancer|Soft Tissue Cancer |
2021-10-26 |
|
| 4WARD Study | P3 |
Completed |
Unknown |
2020-11-16 |
|
| NWU07-9-02 | P2 |
Completed |
Breast Cancer|Intraductal Noninfiltrating Carcinoma|Ductal Carcinoma|Ductal Breast Carcinoma |
2011-09-01 |